[Regulation]Regulation update: EU REACH Annex XVII amendment (Jun. 3, 2025)

29 Jun 2025

On June 3, 2025, the European Commission (EC) issued Regulation (EU) 2025/1090 amending REACH Annex XVII to impose restrictions on DMAC and NEP.

  • Publication in the EU Official Journal (EU 2025/1090): June 3, 2025

  • Date of entry into force: June 23, 2025


Regulation overview

  • EU REACH (Registration, Evaluation, Authorization and Restriction of Chemicals, EC 1907/2006) is the EU’s comprehensive regulatory framework for the management of chemical substances, covering registration, evaluation, authorization, and restriction.

  • When a substance is identified as posing a risk to human health or the environment, EU Member States or the European Chemicals Agency (ECHA) may submit a restriction proposal.

  • Following public consultations and opinion development by expert committees, ECHA submits a recommendation to the European Commission.

  • If the recommendation is accepted, it is published in the EU Official Journal (OJ) and enters into legal force.



Key Changes

  • Addition of Entry 80 (DMAC) and Entry 81 (NEP) to Annex XVII of REACH

  • Substance Details

    • DMAC and NEP are commonly used solvents in industrial applications.

    • Due to concerns over occupational exposure, they have been designated as restricted substances to reduce health risks to workers.

Entry NoNameCASApplications

80


DMAC


127-19-5

Solvent, man-made fibres, varnishes for electrical wire insulation, etc

81


NEP

2687-91-4

Solvent, polymer processing, lubricants, etc




MDSKorea Inc. 

Head Office: 314, Gwanggyojungang-ro, Suji-gu, Yongin-si, Gyeonggi-do, Korea

Seoul Office 1: 173, Digital-ro, Geumcheon-gu, Seoul, Korea

Seoul Office 2: 61, Namhyeon 3-gil, Gwanak-gu, Seoul, Korea

Copyright ⓒ 2023 MDSKorea Inc. All Rights Reserved

Business Registration No.: 142-81-81626 | E-commerce Registration No.: 2024-YonginSuji-1885 

Representative: Yongyeon Hwang


Request a Consultation

Have questions about our services? 

Submit your inquiry, and our team will get back to you promptly.

MDSKorea Inc.

  Head Office

314, Gwanggyojungang-ro, Suji-gu, Yongin-si, Gyeonggi-do, Korea

  Seoul Office

173, Digital-ro, Geumcheon-gu, Seoul, Korea 

  Incheon Office

22, Inha-ro 489beon-gil, Namdong-gu, Incheon, Korea 

ⓒ 2023 MDSKorea Inc. All Rights Reserved